CannaPharmaRx Evaluates Investigation into Market Manipulation and Potentially Illegal Trading of Stock
February 1, 2023
Drug Manufacturers
-
-
CannaPharmaRx Releases Year-in-Review Letter to Shareholders and Discusses Revenue Opportunities for 2023
January 30, 2023
-
Curaleaf Announces Launch of Adult-Use Cannabis Sales at Stamford, CT Dispensary
January 27, 2023
-
Curaleaf Announces Closure of Operations in California, Colorado and Oregon
January 26, 2023
-
Curaleaf Expands Grassroots Premium Cannabis Brand to New Jersey
January 24, 2023
-
22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position
January 24, 2023
-
Panacea Announces Letter of Intent to Acquire N7 Enterprises, Inc.
January 23, 2023
-
Curaleaf Celebrates Opening of Clermont, FL Dispensary
January 23, 2023
-
22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
January 23, 2023
-
Cosmos Health Extends and Updates its Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp
January 20, 2023
-
Livewire’s Estrella River Farms Partners with Cannavision Labs to Ship Second Wave of Estrella Weedery Branded Premium Cannabis Concentrate for California Distribution
January 12, 2023
-
Curaleaf Announces Opening of Palm Beach Gardens Dispensary and Launch of New BlueKudu Chocolates in Florida
January 12, 2023
-
CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected
January 11, 2023
-
Curaleaf Celebrates Launch of Adult-Use Cannabis Sales in Connecticut
January 10, 2023
-
HYLA Division Strongly Positions Endexx Into Early Fiscal 2023 With More Than $3 Million in Purchase Orders Shipped to 11 Countries
January 10, 2023
-
Cosmos Health Regains Nasdaq Minimum Bid Price Compliance
January 5, 2023